Introduction

Explor Drug Sci

EDS

Exploration of Drug Science

2836-7677

Open Exploration Publishing

10.37349/eds.2024.00040

100840

Perspective

Clinical studies with drugs and biologics aimed at slowing or reversing normal aging processes—emerging results and future perspectives

https://orcid.org/0000-0001-6209-926X

Garay

Ricardo P.

Conceptualization Writing—review & editing ¹ ² ^* Sabatier

Jean-Marc

Academic Editor Aix-Marseille University, France

¹Department of Pharmacology and Therapeutics, Craven Center, 91360 Villemoisson-sur-Orge, France ²Department of Life Sciences, Centre National de la Recherche Scientifique, 75016 Paris, France

^* Correspondence: Ricardo P. Garay, Department of Pharmacology and Therapeutics, Craven Center, 46bis, rue Galliéni, 91360 Villemoisson-sur-Orge, France. ricardo.garay@orange.fr

2024

10 04 2024

2 2 144 153 03 08 2023 05 01 2024

This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Five families of investigational products are in clinical investigation to slow or reverse normal aging processes [longevity candidates, mesenchymal stem cells, senolytics drugs, sirtuin activators, and nicotinamide adenine dinucleotide (NAD)⁺ precursors]. The longevity candidates, vitamin D and metformin, appear to significantly reduce all-cause mortality and prolong life expectancy. This should be confirmed by interventional studies. The mesenchymal stem cell family is the most advanced in clinical trial development [phase 2b randomized controlled trial (RCT)]. An allogeneic bone marrow stem cell preparation (Lomecel-B) reduced locomotor frailty in older people. The improvement in locomotion was modest. In the future, attempts could be made to improve potency through a precondition or genetic modification of naive bone marrow stem cells. Autologous adipose stem cell-assisted fat grafting increased graft survival, facial volume, and skin quality. The association of the senolytic drugs dasatinib and quercetin was well tolerated, with low brain penetration of dasatinib and undetectable levels of quercetin. The sirtuin-1 activator resveratrol (combined with physical exercise) improved physical function in older adults with physical limitations. The NAD⁺ precursor nicotinamide riboside improved physical exercise performance. In conclusion, Lomecel-B is the most advanced agent in clinical trial development for normal aging processes (phase 2b for locomotion frailty), followed by resveratrol and nicotinamide riboside.

Aging clinical trials frailty longevity rejuvenation senolytics stem cells vitamin D

Introduction

Aging is characterized by a slow loss of organ function, reducing vitality, resilience, and healthy life expectancy. The International Conference on Frailty and Sarcopenia Research (ICFSR) clinical practice guidelines (CPGs) specify that there is no specific medical or biological treatment for these normal conditions of aging. The ICFSR does not recommend any of the non-specific pharmacological treatments currently available (only therapeutic interventions based on exercise and nutritional supplements are recommended) [1].

A substantial effort is currently deployed to find specific drugs and biologics intended to slow or reverse normal aging processes. Currently, several literature reviews are available that identify and analyze clinical studies with the following specific families of compounds (Table 1): (i) longevity candidates [2, 3], (ii) mesenchymal stem cells [4–6], (iii) senolytics drugs [7–9], (iv) sirtuin activators [10–13], and (v) nicotinamide adenine dinucleotide (NAD)⁺ precursors [14–18].

Table 1

Drugs and biologics that have shown positive results in clinical research to slow or reverse normal aging processes

Family	Indication	Leading agent	Study type	Reference
Longevity candidates	Longevity	Vitamin D	Observational	[34, 36]
Longevity candidates	Longevity	Metformin	Observational	[40]
Mesenchymal stem cells	Locomotion frailty	Lomecel-B	RCT (phase 2)	[47]
Mesenchymal stem cells	Facial rejuvenation	SVF	RCT	[54]
Senolytics drugs	Cognitive decline	D + Q	OL (phase 1)	[58]
Sirtuin activators	Aging frailty	Resveratrol	RCT (phase 2)	[61]
NAD⁺ precursors	Physical performance	NRS	RCT	[65]

SVF: stromal vascular fraction; D + Q: dasatinib and quercetin; NRS: nicotinamide riboside supplements; OL: open-label

An overview of emerging results and future perspectives from clinical studies conducted with the five compound families mentioned above is presented here. Preclinical data and details about ongoing clinical trials (without results) can be found in the literature reviews cited above [2–12, 14, 15]. The reader interested in pharmacological mechanisms and biomarkers can consult the reviews by Nielsen et al. [16], Tchkonia et al. [19], Moskalev et al. [20], and Fraser et al. [21].

Longevity candidates

Twenty years ago, the National Institute on Aging (NIA, USA) launched an Intervention Testing Program (ITP) dedicated to identifying longevity candidates in a genetically heterogeneous mouse model (candidates are evaluated in three independent laboratories) [22]. The ITP has identified two longevity drug candidates, the immunosuppressant rapamycin [23] and the antidiabetic acarbose [24] that are currently under clinical investigation [3]. Vitamin D and the antidiabetic drug metformin have been identified in other animal models and are also under clinical investigation [3, 25].

The mechanism by which these longevity candidates prolong animal lifespan is unclear. Rapamycin is a [mammalian target of rapamycin (mTOR)] kinase inhibitor, which possesses immunosuppressive and antiproliferative properties [25]. Ehninger et al. [26] have suggested that rapamycin extends lifespan in mice by suppressing cancerogenesis. Acarbose is an inhibitor of alpha-glucosidases, a class of intestinal enzymes necessary to digest carbohydrates [27]. Acarbose exerts anti-inflammatory effects on human monocytic THP-1 cells [28], and Sadagurski et al. [29] suggested that acarbose may prolong lifespan in mice by inhibiting age-related hypothalamic inflammation. Metformin appears to exert antiaging actions via multiple mechanisms, including nutrient sensing, DNA repair, oxidative stress, telomere attrition, inflammation, cellular senescence, stem cell decline, and autophagy [30]. Finally, vitamin D is a gene expression modifier (acting on more than 200 genes) and has pleiotropic biological actions [31].

Emerging results with vitamin D

Vitamin D is mainly synthesized in skin exposed to sunlight, and strong sunlight at equatorial latitudes leads to high mean serum concentrations of 25-hydroxy vitamin D [25(OH)D = around 115 nmol/L] [32]. On the contrary, low levels of 25(OH)D (< 50 nmol/L) have been found in a considerable proportion of individuals from temperate countries, 40% in Europe and 24% in the USA [33]. In China, the prevalence of vitamin D deficiency in older adults was 68.4% (in 2014) [34, 35].

A recent observational and Mendelian analysis in middle-aged European persons [36] suggested a causal relationship between low levels of 25(OH)D (< 40 nmol/L) and all-cause mortality. In China, all-cause mortality was significantly higher in subjects with low vitamin D status, and the change from vitamin D deficiency to no deficiency was associated with a lower risk of all‐cause mortality [34].

Emerging results with metformin

Kulkarni et al. [37] conducted a phase 4, crossover design RCT (ClinicalTrials.gov identifier: NCT02432287) to investigate the effect of metformin on metabolic and nonmetabolic regulation pathways in skeletal muscle and subcutaneous adipose tissue from 14 older adults (around 70 years old). Participants received oral metformin (1,700 mg/day) or placebo for 6 weeks. Metformin was found to significantly modify gene expression (RNA sequencing) in biopsies from skeletal muscle (647 genes) and subcutaneous adipose tissue (146 genes) [37]. These transcriptomic changes included several well-known anti-aging genes from the GenAge database [37, 38]. In addition, a Mendelian randomization study using UK Biobank data [39] showed that metformin use was associated with younger phenotypic age.

Campbell et al. [40] reviewed observational studies comparing all-cause mortality in patients with diabetes taking metformin with non-diabetics, or with diabetics receiving non-metformin therapies. The results suggested that metformin reduces all-cause mortality independently of its antidiabetic effect [40].

Several clinical trials have been conducted with metformin for aging-related diseases, but they are outside the scope of this article for a recent review, see [41].

Perspectives of clinical research with longevity candidates

All-cause mortality is a marker of longevity [3]. The above results from observational studies suggest that vitamin D supplementation [in persons with low 25(OH)D serum levels] [34, 36] as well as metformin [40] can significantly reduce all-cause mortality and prolong life expectancy (Table 1). This prolongevity efficacy should be confirmed by interventional studies.

A phase 3 clinical trial with metformin [Targeting Aging with Metformin (TAME)] was planned to assess the time to new onset of a composite outcome including cardiovascular events, cancer, dementia, and mortality [42, 43]. TAME plans to include 3,000 participants, aged 65–79 years, at 14 centers across the US. In 2015, TAME started a discussion with the Food and Drug Administration (FDA, USA), but to this day it is not included in the ClinicalTrials.gov database.

According to Barzilai et al. [43], the goal of TAME was to demonstrate “that metformin modulates aging and its diseases, beyond an isolated impact on diabetes”. According to Glossmann and Lutz [44]: “The acronym chosen and the intention behind it – namely, that aging is a ‘disorder’ that can be treated like any other disease – was a clear provocation.”.

It is interesting to mention that two other longevity candidates (rapamycin and acarbose) are currently in clinical trials, but the results have not yet been reported to ClinicalTrials.gov [3].

Mesenchymal stem cell preparations

Mesenchymal stem cell preparations and multipotential stromal cells were in development for locomotion frailty and facial skin aging [4].

Positive results on locomotion frailty

Physical frailty in the elderly is characterized by reduced locomotor activity [1], and locomotion frailty is associated with an increased risk of falls, disability, and hospitalization [45].

Lomecel-B (Longeveron, USA) is an allogeneic bone marrow stem cell preparation expanded in culture [46]. The [allogeneiC human mesenchymal stem cells in patients with aging fRAilTy via intravenoUS delivery (CRATUS)] trial [46, 47] included: (i) a phase 1 safety study in 15 frail aging patients followed for 1 month [46], and (ii) a phase 2 RCT [47] investigating the efficacy of intravenous Lomecel-B to reduce physical frailty in 30 elderly subjects with mild to moderate locomotion frailty (treatment period: 6 months). The phase 1 study showed that Lomecel-B was safe and immunologically tolerated [46]. Participants in the phase 2 RCT [47] received 100 million cells (n = 10), 200 million cells (n = 10), or placebo (n = 10). The 6-min walk distance (6-MWD) increased significantly in the 100 m group (from 345.9 m to 410.5 m, mean values at baseline and 6 months, respectively). Immunotolerability was acceptable. Tumor necrosis factor (TNF)-alpha levels decreased significantly.

Lomecel-B is a candidate for further development in phase 3 trials.

Perspectives of clinical research with stem cell preparations for physical frailty

Locomotion frailty improvement with intravenous Lomecel-B was modest [48]. Preconditioning of naive bone marrow stem cells (with growth factors, drugs, or other agents), as well as genetic modification, can improve their therapeutic efficacy [49]. On the other hand, intravenous administration risks trapping the stem cells in the lungs [50]. In such a case, (smaller) exosomes may be an option to increase efficacy.

Several other phase 1 and 2 clinical trials with stem cell preparations are currently underway [4]. In particular, a clinical trial (NCT04314011) using an allogeneic preparation of umbilical cord-derived stem cells was recently completed, but the results have not yet been reported to ClinicalTrials.gov.

The use of allogeneic stem cell preparations may limit its clinical application. Predictive markers of graft rejection are being developed [51], markers that could help identify patients at risk of tissue rejection before administering stem cells.

Positive results on facial skin aging

Facial skin aging is due to natural causes, as well as extrinsic factors (especially sun exposure: photoaging). The [stromal vascular fraction (SVF)] is a preparation of human adipose stem cells obtained by liposuction, followed by collagenase digestion and centrifugation [4, 52, 53]. Yin et al. [54] conducted an RCT to investigate autologous SVF-assisted fat grafting for facial rejuvenation. Fifty patients were randomly assigned into two groups: an intervention group (n = 25) and a control group (n = 25, fat grafting only). SVF-assisted autologous fat grafting increased graft survival, facial volume, and skin quality (Table 1).

Perspectives of clinical research with stem cell preparations for facial rejuvenation

Several clinical trials for facial skin aging are currently underway in Egypt, Indonesia, Cuba, Iran, and Malaysia [4]. Autologous SVF preparations are regulated as biological products by the FDA (USA) because they require mechanical processing [4, 41], and very numerous clinical trials with autologous SVF preparations for facial rejuvenation [53] are not registered on ClinicalTrials.gov. This was not the case with the study of Yin et al. [54], which was registered in ClinicalTrials.gov (NCT02923219) as well as other clinical trials conducted in Egypt (NCT03928444) and Indonesia (NCT05508191) [4]. Results from trials NCT03928444 and NCT05508191 have not yet been posted to ClinicalTrials.gov. The application of similar RCT protocols could pave the way for autologous SVF preparations (in the USA) to be registered on ClinicalTrials.gov and comply with FDA regulations.

Senolytic drugs

Cellular senescence stops the proliferation of damaged or dysfunctional cells [7]. Aging is associated with the accumulation of senescent cells in various tissues and organs. In 2011, the group of Baker et al. [55] showed that killing senescent cells using a transgenic suicide gene is beneficial in preventing or delaying tissue dysfunction and prolonging lifespan in mouse models. Subsequently, the same group reported the discovery of senolytic agents in animal models: (i) the combination of D + Q in 2015 [56], and (ii) fisetin in 2017 [57].

Results

Gonzales et al. [58] recently reported the results of a 12 week, phase 1 clinical trial investigating the safety and cerebrospinal fluid (CSF) penetrance of D + Q in 5 participants (aged 70 years to 82 years) with early-stage symptomatic Alzheimer’s disease (Table 1). D + Q (100 mg and 1,000 mg respectively) were orally given for two days, followed by a treatment interruption of 13 days to 15 days, for a total of 6 cycles. Treatment was well tolerated and was not discontinued prematurely [58]. Low levels of dasatinib were detected in the CSF of 4 participants. Quercetin was not detectable in the CSF.

Perspectives

Several senolytics, including D + Q and fisetin, are in development for cognitive decline [59], aging frailty, and skeletal health in normal postmenopausal women [7]. A clear advantage of some senolytics (quercetin, fisetin) is that they are natural products [60], but it seems too early to draw conclusions about clinical research with senolytic agents.

Sirtuin activators

Human sirtuins are a family of 7 signaling NAD⁺-dependent protein deacetylases that are involved in metabolic regulation, resistance to stress, and cellular processes, including aging and cell death [10, 11]. The natural polyphenol resveratrol is a powerful activator of sirtuin-1 (SIRT1) [12, 13]. Curcumin (another natural polyphenol) is a non-specific activator/upregulator of sirtuins (mainly influencing SIRT1 and SIRT3) [13].

Positive results

Harper et al. [61] have recently conducted a pilot clinical trial showing that resveratrol and exercise combined improve aging frailty (Table 1).

Perspectives

The positive results of the pilot trial by Harper et al. [61] deserve confirmation in larger-scale trials.

NAD<sup>+</sup> precursors

A large body of evidence clearly shows that aging is associated with a reduction in cellular NAD⁺ levels [14–18]. In particular, Mouchiroud et al. [62] found that NAD⁺ levels are reduced in aged worms (the nematode Caenorhabditis elegans) and aged mice and that decreasing NAD⁺ levels reduced worm lifespan. Zhu et al. [63] reported a decrease in intracellular NAD⁺ levels in the healthy aged human brain in vivo. Massudi et al. [64] found a strong negative correlation between age and NAD⁺ levels in human pelvic skin samples.

Barker et al. [14] published a systematic review of 26 trials that investigated the effect of NAD⁺ precursors on physical frailty outcomes. Only four of these trials enrolled participants with a mean age of 60 years or more [14]. Of these, only two trials included healthy participants. Dolopikou et al. [65] found that NRS significantly improved exercise performance (isometric peak torque and fatigue index) in the elderly. Martens et al. [66] reported that NRS elevates NAD⁺ levels in circulating peripheral blood mononuclear cells of healthy middle-aged and older adults.

Concluding remarks

Clinical research with drugs and biologics intended to slow or reverse normal aging processes has only recently begun [2–18]. Positive results are beginning to emerge from the very numerous clinical trials (and observational studies) launched worldwide (Table 1).

Research highlights and perspectives:

(1)

Vitamin D and metformin are leaders in the clinical development of longevity candidates (Table 1). Observational studies strongly suggested that these compounds can significantly reduce all-cause mortality (and prolong life expectancy) (Table 1). This prolongevity efficacy should be confirmed by interventional studies.

(2)

Intravenous Lomecel-B (a mesenchymal stem cell preparation) showed efficacy in reducing locomotor frailty in older people. However, the frailty improvement was modest. Preconditioning and/or genetic modification of naive mesenchymal stem cells can improve their therapeutic efficacy. The use of allogeneic stem cell preparations may limit its clinical application. Predictive markers of graft rejection are being developed, markers that could help identify patients at risk of tissue rejection before administering stem cells.

(3)

An RCT on facial rejuvenation [54] was registered on ClinicalTrials.gov (NCT02923219) and showed that an autologous fat graft enriched with human adipose tissue stem cells improves graft survival, facial volume, and skin quality. The application of a similar RCT protocol could pave the way for autologous SVF preparations to be registered on ClinicalTrials.gov and comply with FDA regulations.

(4)

Senolytic drugs (including D + Q and fisetin), the SIRT1 activator resveratrol, and the NAD⁺ precursor nicotinamide riboside (NR) are being developed to slow normal aging processes, but it seems too early to draw conclusions about the current clinical research with these compounds.

Abbreviations

25(OH)D

25-hydroxy vitamin D

CSF

cerebrospinal fluid

D + Q

dasatinib and quercetin

FDA

Food and Drug Administration

NAD

nicotinamide adenine dinucleotide

NRS

nicotinamide riboside supplements

RCT

randomized controlled trial

SIRT1

sirtuin-1

SVF

stromal vascular fraction

TAME

Targeting Aging with Metformin

Declarations Author contributions

RPG: Conceptualization, Writing—review & editing.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Dent

Morley

Cruz-Jentoft

Woodhouse

Rodríguez-Mañas

Fried

et al.

Physical frailty: ICFSR international clinical practice guidelines for identification and management

J Nutr Health Aging 2019 23 771 87

10.1007/s12603-019-1273-z

31641726

PMC6800406

Laskovs

Partridge

Slack

Molecular inhibition of RAS signalling to target ageing and age-related health

Dis Model Mech 2022 15

dmm049627

10.1242/dmm.049627

36111627

PMC9510030

Garay

Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu

Expert Opin Investig Drugs 2021 30 749 58

10.1080/13543784.2021.1939306

34081543

Garay

Recent clinical trials with stem cells to slow or reverse normal aging processes

Front Aging 2023 4

1148926

10.3389/fragi.2023.1148926

37090485

PMC10116573

Sun

Hao

Tang

Xiao

Dong

Frailty and rejuvenation with stem cells: therapeutic opportunities and clinical challenges

Rejuvenation Res 2019 22 484 97

10.1089/rej.2017.2048

30693831

PMC6919243

Zhu

Huang

Liu

Jiang

Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics

Theranostics 2021 11 5675 85

10.7150/thno.46436

33897874

PMC8058725

Chaib

Tchkonia

Kirkland

Cellular senescence and senolytics: the path to the clinic

Nat Med 2022 28 1556 68

10.1038/s41591-022-01923-y

35953721

PMC9599677

Wyles

Tchkonia

Kirkland

Targeting cellular senescence for age-related diseases: path to clinical translation

Plast Reconstr Surg 2022 150

10.1097/PRS.0000000000009669

36170432

PMC9529239

Zhang

Pitcher

Prahalad

Niedernhofer

Robbins

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

FEBS J 2023 290 1362 83

10.1111/febs.16350

35015337

Dai

Sinclair

Ellis

Steegborn

Sirtuin activators and inhibitors: promises, achievements, and challenges

Pharmacol Ther 2018 188 140 54

10.1016/j.pharmthera.2018.03.004

29577959

PMC6342514

Watroba

Szukiewicz

Sirtuins at the service of healthy longevity

Front Physiol 2021 12

724506

10.3389/fphys.2021.724506

34899370

PMC8656451

Toniolo

Concato

Giacomello

Resveratrol, a multitasking molecule that improves skeletal muscle health

Nutrients 2023 15

3413

10.3390/nu15153413

37571349

PMC10421121

Wiciński

Erdmann

Nowacka

Kuźmiński

Michalak

Janowski

et al.

Natural phytochemicals as SIRT activators—focus on potential biochemical mechanisms

Nutrients 2023 15

3578

10.3390/nu15163578

37630770

PMC10459499

Barker

Hart

Sayer

Witham

Effects of nicotinamide adenine dinucleotide precursors on measures of physical performance and physical frailty: a systematic review

JCSM Clin Rep 2022 7 93 106

10.1002/crt2.56

Reiten

Wilvang

Mitchell

Fang

Preclinical and clinical evidence of NAD⁺ precursors in health, disease, and ageing

Mech Ageing Dev 2021 199

111567

10.1016/j.mad.2021.111567

34517020

Nielsen

Bakula

Scheibye-Knudsen

Clinical trials targeting aging

Front Aging 2022 3

820215

10.3389/fragi.2022.820215

Fang

Lautrup

Hou

Demarest

Croteau

Mattson

et al.

NAD⁺ in aging: molecular mechanisms and translational implications

Trends Mol Med 2017 23 899 916

10.1016/j.molmed.2017.08.001

28899755

PMC7494058

Yoshino

Baur

Imai

NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR

Cell Metab 2018 27 513 28

10.1016/j.cmet.2017.11.002

29249689

PMC5842119

Tchkonia

Palmer

Kirkland

New horizons: novel approaches to enhance healthspan through targeting cellular senescence and related aging mechanisms

J Clin Endocrinol Metab 2021 106 e1481 7

10.1210/clinem/dgaa728

33155651

PMC7947756

Moskalev

Guvatova

Lopes

Beckett

Kennedy

Magalhaes JP

et al.

Targeting aging mechanisms: pharmacological perspectives

Trends Endocrinol Metab 2022 33 266 80

10.1016/j.tem.2022.01.007

35183431

Fraser

Kuan

Johnen

Zwierzyna

Hingorani

Beyer

et al.

Biological mechanisms of aging predict age-related disease co-occurrence in patients

Aging Cell 2022 21

e13524

10.1111/acel.13524

35259281

PMC9009120

ITP [Internet]

[cited 2023 Jul 28]. Available from: https://www.nia.nih.gov/research/dab/interventions-testing-program-itp

Harrison

Strong

Sharp

Nelson

Astle

Flurkey

et al.

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Nature 2009 460 392 5

10.1038/nature08221

Harrison

Strong

Allison

Ames

Astle

Atamna

et al.

Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males

Aging Cell 2014 13 273 82

10.1111/acel.12170

24245565

PMC3954939

Huggins

Farris

Vitamin D₃ promotes longevity in Caenorhabditis elegans

Geroscience 2023 45 345 58

10.1007/s11357-022-00637-w

Ehninger

Neff

Xie

Longevity, aging and rapamycin

Cell Mol Life Sci 2014 71 4325 46

10.1007/s00018-014-1677-1

25015322

PMC4207939

DiNicolantonio

Bhutani

O’Keefe

Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes

Open Heart 2015 2

e000327

10.1136/openhrt-2015-000327

26512331

PMC4620230

Lin

Chen

Hsiao

Kuo

Chen

et al.

The effects of acarbose on chemokine and cytokine production in human monocytic THP-1 cells

Hormones (Athens) 2019 18 179 87

10.1007/s42000-019-00101-z

30827017

Sadagurski

Cady

Miller

Anti-aging drugs reduce hypothalamic inflammation in a sex-specific manner

Aging Cell 2017 16 652 60

10.1111/acel.12590

28544365

PMC5506421

Cheng

Liu

Lin

Metformin’s mechanisms in attenuating hallmarks of aging and age-related disease

Aging Dis 2022 13 970 86

10.14336/AD.2021.1213

35855344

PMC9286921

Ramagopalan

Heger

Berlanga

Maugeri

Lincoln

Burrell

et al.

A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution

Genome Res 2010 20 1352 60

10.1101/gr.107920.110

20736230

PMC2945184

Luxwolda

Kuipers

Kema

Dijck-Brouwer

Muskiet

Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l

Br J Nutr 2012 108 1557 61

10.1017/S0007114511007161

22264449

Amrein

Scherkl

Hoffmann

Neuwersch-Sommeregger

Köstenberger

Tmava

Berisha A

et al.

Vitamin D deficiency 2.0: an update on the current status worldwide

Eur J Clin Nutr 2020 74 1498 513

10.1038/s41430-020-0558-y

31959942

PMC7091696

Zeng

Sun

Miao

Wang

et al.

Change of vitamin D status and all-cause mortality among Chinese older adults: a population-based cohort study

BMC Geriatr 2022 22

245

10.1186/s12877-022-02956-1

35331164

PMC8944012

Chinese longitudinal healthy longevity survey (CLHLS), 1998-2014 [Internet]

The Regents of the University of Michigan; c2024 [cited 2023 Aug 2]. Available from: https://doi.org/10.3886/ICPSR36692.v1

Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses

Lancet Diabetes Endocrinol 2024 12 e2 11

10.1016/S2213-8587(21)00263-1

34717822

PMC8600124

Kulkarni

Brutsaert

Anghel

Zhang

Bloomgarden

Pollak

et al.

Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults

Aging Cell 2018 17

e12723

10.1111/acel.12723

29383869

PMC5847877

Tacutu

Craig

Budovsky

Wuttke

Lehmann

Taranukha

et al.

Human ageing genomic resources: integrated databases and tools for the biology and genetics of ageing

Nucleic Acids Res 2013 41 D1027 33

10.1093/nar/gks1155

23193293

PMC3531213

Luo

Wong

ICK

Chui

CSL

Zheng

Huang

Schooling

et al.

Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank

Lancet Healthy Longev 2023 4 e337 44

10.1016/S2666-7568(23)00085-5

37421961

Campbell

Bellman

Stephenson

Lisy

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis

Ageing Res Rev 2017 40 31 44

10.1016/j.arr.2017.08.003

28802803

Overview on the regulation of cellular therapies in aesthetic medicine [Internet]

[cited 2023 Aug 2]. Available from: https://www.aslms.org/docs/default-source/for-professionals/resources/task-force-whitepaper-2019-final-4-9-21.pdf

Padki

Stambler

Targeting aging with metformin (TAME)

Dupre

Encyclopedia of gerontology and population aging Cham

Springer International Publishing

2021 pp. 4908–10.

Barzilai

Crandall

Kritchevsky

Espeland

Metformin as a tool to target aging

Cell Metab 2016 23 1060 5

10.1016/j.cmet.2016.05.011

27304507

PMC5943638

Glossmann

Lutz

OMD

Metformin and aging: a review

Gerontology 2019 65 581 90

10.1159/000502257

31522175

Xue

The frailty syndrome: definition and natural history

Clin Geriatr Med 2011 27 1 15

10.1016/j.cger.2010.08.009

21093718

PMC3028599

Golpanian

DiFede

Khan

Schulman

Landin

Tompkins

et al.

Allogeneic human mesenchymal stem cell infusions for aging frailty

J Gerontol A Biol Sci Med Sci 2017 72 1505 12

10.1093/gerona/glx056

28444181

PMC5861970

Tompkins

DiFede

Khan

Landin

Schulman

Pujol

et al.

Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial

J Gerontol A Biol Sci Med Sci 2017 72 1513 22

10.1093/gerona/glx137

28977399

PMC5861900

Larrick

Mendelsohn

Mesenchymal stem cells for frailty?

Rejuvenation Res 2017 20 525 9

10.1089/rej.2017.2042

29179649

Ocansey

DKW

Pei

Yan

Qian

Zhang

et al.

Improved therapeutics of modified mesenchymal stem cells: an update

J Transl Med 2020 18

10.1186/s12967-020-02234-x

32000804

PMC6993499

Salvadori

Cesari

Murgia

Puccini

Riccardi

Dominici

Dissecting the pharmacodynamics and pharmacokinetics of mscs to overcome limitations in their clinical translation

Mol Ther Methods Clin Dev 2019 14 1 15

10.1016/j.omtm.2019.05.004

31236426

PMC6581775

Kadri

Amu

Iacobaeus

Boberg

Blanc K

Current perspectives on mesenchymal stromal cell therapy for graft versus host disease

Cell Mol Immunol 2023 20 613 25

10.1038/s41423-023-01022-z

37165014

PMC10229573

Coleman

The technique of periorbital lipoinfiltration

Oper Tech Plast Reconstr Surg 1994 1 120 6

10.1016/S1071-0949(10)80002-2

Surowiecka

Strużyna

Adipose-derived stem cells for facial rejuvenation

J Pers Med 2022 12

117

10.3390/jpm12010117

35055432

PMC8781097

Yin

Zhang

Jin

Autologous fat graft assisted by stromal vascular fraction improves facial skin quality: a randomized controlled trial

J Plast Reconstr Aesthet Surg 2020 73 1166 73

10.1016/j.bjps.2019.11.010

32269011

Baker

Wijshake

Tchkonia

LeBrasseur

Childs

van de Sluis

et al.

Clearance of p16^Ink4a-positive senescent cells delays ageing-associated disorders

Nature 2011 479 232 6

10.1038/nature10600

22048312

PMC3468323

Zhu

Tchkonia

Pirtskhalava

Gower

Ding

Giorgadze

et al.

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Aging Cell 2015 14 644 58

10.1111/acel.12344

25754370

PMC4531078

Zhu

Doornebal

Pirtskhalava

Giorgadze

Wentworth

Fuhrmann-Stroissnigg

et al.

New agents that target senescent cells: the flavone, fisetin, and the BCL-X_L inhibitors, A1331852 and A1155463

Aging (Albany NY) 2017 9 955 63

10.18632/aging.101202

28273655

PMC5391241

Gonzales

Garbarino

Kautz

Palavicini

Lopez-Cruzan

Dehkordi

et al.

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial

Nat Med 2023 29 2481 8

10.1038/s41591-023-02543-w

37679434

PMC10875739

Orr

Gonzales

Garbarino

Kautz

Palavicini

Lopez-Cruzan

et al.

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – outcomes from the first clinical trial of senolytic therapy for Alzheimer’s disease

[Preprint]. 2023 [cited 2023 Aug 2]. Available from: https://www.researchsquare.com/article/rs-2809973/v1

Barrera-Vázquez

Magos-Guerrero

Escobar-Ramírez

Gomez-Verjan

Natural products as a major source of candidates for potential senolytic compounds obtained by in silico screening

Med Chem 2023 19 653 68

10.2174/1573406419666221019153537

36278464

Harper

Bassler

Peramsetty

Yang

Roberts

Drummer

et al.

Resveratrol and exercise combined to treat functional limitations in late life: a pilot randomized controlled trial

Exp Gerontol 2021 143

111111

10.1016/j.exger.2020.111111

33068691

PMC7855904

Mouchiroud

Houtkooper

Moullan

Katsyuba

Ryu

Cantó

et al.

The NAD⁺/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling

Cell 2013 154 430 41

10.1016/j.cell.2013.06.016

23870130

PMC3753670

Zhu

Lee

Ugurbil

Chen

In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences

Proc Natl Acad Sci U S A 2015 112 2876 81

10.1073/pnas.1417921112

25730862

PMC4352772

Massudi

Grant

Braidy

Guest

Farnsworth

Guillemin

Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue

PLoS One 2012 7

e42357

10.1371/journal.pone.0042357

22848760

PMC3407129

Dolopikou

Kourtzidis

Margaritelis

Vrabas

Koidou

Kyparos

et al.

Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study

Eur J Nutr 2020 59 505 15

10.1007/s00394-019-01919-4

30725213

Martens

Denman

Mazzo

Armstrong

Reisdorph

McQueen

et al.

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults

Nat Commun 2018 9

1286

10.1038/s41467-018-03421-7

29599478

PMC5876407